This page lists the surgical oncology hospitals in our directory offering Stomach Cancer Treatment in Dubai, UAE, including Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai. Each listing links through to the hospital's full profile page.
Ask us about stomach cancer treatment in Dubai, UAE
Share a few details and our care coordination team will get back to you with next steps.
Compare 3 accredited hospitals for Surgical Oncology in Dubai, UAE
🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
🇦🇪 Kings College Hospital Dubai
🇦🇪 Aster Hospital Dubai
How we selected these hospitals
A hospital appears on this page when Surgical Oncology is among its listed specialties and it is located in Dubai, UAE. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Stomach Cancer Treatment in Dubai, UAE?
Choosing the right hospital for stomach cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include surgical oncology rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Stomach Cancer Treatment
Stomach cancer (gastric adenocarcinoma) is treated through a multidisciplinary protocol combining surgery, perioperative chemotherapy, targeted therapy, and—where indicated—immunotherapy; experienced oncology centers in India and the UAE achieve 5-year overall survival rates of 30–60% depending on stage at diagnosis. International patients choose GAF Healthcare to access high-volume gastric oncology units staffed by surgeons trained at leading Western and Asian cancer institutes, at a fraction of the cost they would pay at home. GAF Healthcare coordinates every clinical and logistical detail—from staging workup through post-operative surveillance—across its partner network of NABH- and JCI-accredited hospitals in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi.
Clinical Overview
Gastric cancer arises predominantly from the glandular epithelium of the stomach lining (adenocarcinoma in ~95% of cases) and is further classified by anatomic location (cardia/gastro-esophageal junction vs. body vs. antrum/pylorus), Lauren histological subtype (intestinal, diffuse, or mixed), and molecular subtype per The Cancer Genome Atlas (TCGA) classification—Epstein-Barr virus-positive, microsatellite instable (MSI-H), chromosomally instable (CIN), and genomically stable (GS). Helicobacter pylori infection, atrophic gastritis, intestinal metaplasia, smoking, high-salt diets, and hereditary diffuse gastric cancer (CDH1 germline mutations) are the principal etiological drivers. Physiologically, tumor growth disrupts gastric acid secretion, impairs digestion, and commonly causes protein-calorie malnutrition; advanced disease may obstruct the gastric outlet or invade adjacent structures (pancreas, transverse colon, liver), producing ascites, peritoneal carcinomatosis, or hepatic metastases.
Full details →Who is a Candidate?
- ELIGIBLE FOR CURATIVE SURGICAL RESECTION:
- Clinical stage IA–IIIC (cT1–T4a, N0–N3, M0) confirmed by EUS, CT, PET-CT, and diagnostic laparoscopy
- Adequate cardiopulmonary reserve: ECOG performance status 0–2; left ventricular ejection fraction ≥50% (required before anthracycline-based chemotherapy); FEV1 ≥1.0 L for total gastrectomy candidates
- Nutritional optimization achievable: albumin >3.0 g/dL or correctable with pre-operative enteral nutrition; BMI considerations reviewed by bariatric-oncology team
- Absence of peritoneal carcinomatosis on diagnostic laparoscopy with negative peritoneal cytology
- +21 more
Treatment Options & Approaches
Surgical APPROACHES:
1. Distal (Subtotal) Gastrectomy with D2 Lymphadenectomy:
Indicated for tumors of the antrum and pylorus (lower two-thirds of the stomach). At least 4–5 cm proximal margin from the tumor is required. Reconstruction is performed via Billroth II (gastrojejunostomy) or Roux-en-Y configuration to prevent bile reflux. D2 dissection removes lymph node stations 1–12 as defined by the Japanese Gastric Cancer Association (JGCA), and retrieval of a minimum of 16 lymph nodes is required for accurate N-staging. D2 lymphadenectomy is the global standard and is associated with superior disease-specific survival compared to D1 in high-volume centers.
2. Total Gastrectomy with D2 Lymphadenectomy:
Full details →Recovery
PHASE 1 — PRE-ARRIVAL PREPARATION (Weeks 1–3 before travel):
- GAF Healthcare coordinator collects existing pathology reports, imaging (CT/PET-CT DICOM files), endoscopy reports, and blood work and submits to the designated oncology team for remote multidisciplinary tumor board review.
- A written second-opinion report and individualized treatment plan (surgical vs. chemotherapy-first vs. palliative) is issued within 5–7 business days.
- Visa assistance initiated: e-Medical visa (India) processed in 3–5 business days; UAE entry visa or visa-on-arrival arranged as applicable.
- Nutritional prehabilitation initiated: patients with albumin <3.0 g/dL begin enteral or high-protein oral supplementation; smoking cessation mandatory.
- FLOT pre-operative chemotherapy (if applicable) may begin at the patient's home country after protocol review, or at the partner center after arrival.
PHASE 2 — ARRIVAL & STAGING CONFIRMATION (Days 1–4 in country):
Full details →Risks to be aware of
Stomach cancer surgery and multimodal treatment carry significant risks that patients must discuss in detail with their multidisciplinary team before proceeding. Surgical risks include anastomotic leak (incidence 2–8% after total gastrectomy; managed with radiologically guided drainage or reoperation), duodenal stump blow-out (rare, ~1–2%, life-threatening), intra-abdominal abscess, delayed gastric emptying, and bile reflux gastritis. The Clavien-Dindo classification is used at all GAF partner centers to grade and benchmark post-operative complications; 30-day mortality at high-volume JCI-accredited centers is <2% for elective gastrectomy. Dumping syndrome (early and late) affects 10–20% of patients and requires strict dietary management. Nutritional deficiencies—particularly vitamin B12, iron, calcium, and fat-soluble vitamins—are universal after total gastrectomy and require lifelong supplementation. Chemotherapy-specific risks include peripheral neuropathy (oxaliplatin, cumulative and dose-dependent), febrile neutropenia (FLOT: ~25% incidence; managed with G-CSF), hand-foot syndrome (capecitabine), and cardiotoxicity (anthracyclines used in ECX/ECF regimens, less common with FLOT). Trastuzumab carries a 4–8% risk of asymptomatic left ventricular dysfunction and requires ECHO monitoring every 3 cycles. Immune checkpoint inhibitors (nivolumab, pembrolizumab) may cause immune-related adverse events (irAEs) including immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and severe skin reactions (grade 3–4 irAE incidence ~14%); high-dose corticosteroid management protocols are in place at all partner centers. For international patients specifically, the risks of long-haul air travel following major abdominal surgery include deep vein thrombosis (DVT) and pulmonary embolism; all patients traveling internationally post-gastrectomy receive individualized DVT prophylaxis plans including low-molecular-weight heparin, compression stockings, and in-flight mobility guidance. GAF Healthcare's clinical coordinators monitor all patients until fit-to-fly criteria are met and coordinate emergency medical support in the rare event of post-discharge complications.
Why GAF Healthcare
GAF Healthcare provides a dedicated end-to-end non-medical support infrastructure designed specifically for international oncology patients.
Common questions about Stomach Cancer Treatment
What is the cost of Stomach Cancer Treatment in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after stomach cancer surgery?
What is the success rate of stomach cancer treatment?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Stomach Cancer Treatment in Dubai, UAE
Discover the Top Hospitals for Stomach Cancer Treatment in Dubai, UAE
This page lists 3 accredited surgical oncology hospitals in Dubai, UAE, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about stomach cancer treatment in Dubai, UAE
How many surgical oncology hospitals are listed in Dubai, UAE?
How do you choose which hospitals to list?
How much does treatment cost in UAE?
Are there surgical oncology hospitals for this in other UAE cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for stomach cancer treatment in Dubai, UAE.
Contact us to report an inaccuracy on this page.
